探花合集 Appoints Corporate Development and Science Leaders to Drive Growth and Innovation
SOMERSET, N.J. 鈥 November 19, 2019 鈥 探花合集, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced it has appointed Mike Grippo as Senior Vice President, Strategy and Corporate Development. In this newly created role, Mr. Grippo will be responsible for identifying and evaluating organic and inorganic growth opportunities across 探花合集 that will drive long-term shareholder value. He will report to John Chiminski, 探花合集鈥檚 Chair and CEO.
Mr. Grippo joined 探花合集 as Vice President of Corporate Development in 2016, and in his new role will oversee the strategy and corporate development functions of the company, as well as 探花合集鈥檚 scientific team.
Alongside his appointment, Julien Meissonnier has been named as Vice President and Chief Scientific Officer, and will report to Mr. Grippo. In this new role, Mr. Meissonnier will join the executive leadership team, leading 探花合集鈥檚 new product development and technology innovation programs. He will also head up the company鈥檚 scientific community and customer advisory partnerships to help improve formulation and adoption of drug delivery technologies. Mr. Meissonnier will continue to co-chair the 探花合集 Applied Drug Delivery Institute to leverage emerging new therapeutic modalities.
鈥淪ince our IPO in 2014, we have completed seven acquisitions and are expected to close the acquisition of an oral dose and biologics facility in Italy, from Bristol-Myers Squibb, before the end of the calendar year,鈥 commented John Chiminski. 鈥淭he decisions to make strategic investments in areas such as biologics, gene therapy, and spray drying have been driven in large part by the work of our Corporate Development team, led by Mike Grippo in partnership with key leaders across the business.鈥 He added, 鈥淒uring his long career with 探花合集, Julien has been instrumental in driving excellence across the R&D community, notably through the launch of the Scientific Resource Center serving the business鈥檚 team of approximately 2,400 scientists and technicians. He will promote open innovation within the organization, and we welcome both to the executive leadership team.鈥
Prior to joining 探花合集, Mr. Grippo was Vice President of Corporate Development for CR Bard. Prior to CR Bard, he held a similar leadership role with Hill-Rom Holdings. Earlier in his career he also held positions with SG Cowen and UBS Securities. Mr. Grippo holds a bachelor鈥檚 degree from Princeton University and earned an MBA in Finance from New York University.
Before his appointment as Vice President and Chief Scientific Officer, Mr. Meissonnier previously held the position of Vice President, Science and Technology, and before that led 探花合集鈥檚 European softgel R&D team. He holds an engineering degree in physico-chemistry from the ENSI in Caen, France.
Notes for Editors
ABOUT CATALENT
探花合集 is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, 探花合集 has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. 探花合集 employs nearly 13,000 people, including approximately 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. 探花合集 is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com